JBC INTERFERin siRNA transfection reagent

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M600030200 on February 17, 2006

J. Biol. Chem., Vol. 281, Issue 22, 15090-15098, June 2, 2006
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
281/22/15090    most recent
M600030200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Popov, Y.
Right arrow Articles by Schuppan, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Popov, Y.
Right arrow Articles by Schuppan, D.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Halofuginone Induces Matrix Metalloproteinases in Rat Hepatic Stellate Cells via Activation of p38 and NF{kappa}B*

Yury Popov{ddagger}§1, Eleonora Patsenker{ddagger}2, Michael Bauer{ddagger}, Edith Niedobitek{ddagger}, Anja Schulze-Krebs{ddagger}, and Detlef Schuppan{ddagger}§3

From the {ddagger}Department of Medicine I, University of Erlangen-Nuernberg, 91054 Erlangen, Germany and the §Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02115

The semisynthetic plant alkaloid halofuginone (HAL) was reported to prevent and partly reverse experimental liver fibrosis. However, its mechanisms of action are poorly understood. We therefore aimed to determine the antifibrotic potential of HAL and to characterize involved signal transduction pathways in hepatic stellate cells (HSCs). Results were compared with its in vivo effects in a rat model of reversal of established liver fibrosis induced by thioacetamide. In vitro HAL inhibited HSC proliferation and migration dose dependently at submicromolar concentrations. HAL (200 nM) up-regulated matrix metalloproteinase (MMP)-3 and MMP-13 expression between 10- and 50-fold, resulting in a 2- to 3-fold increase of interstitial collagenase activity. Procollagen {alpha}1(I) and MMP-2 transcript levels were suppressed 2- to 3-fold, whereas expression of other profibrogenic mRNAs remained unaffected. p38 mitogen-activated protein kinase (p38 MAPK) and nuclear factor {kappa}B(NF{kappa}B) pathways were activated by HAL, and specific inhibitors of p38 MAPK and NF{kappa}B dose dependently inhibited MMP-13 induction. Treatment with HAL did not affect HSC viability, and observed effects were reversible after its removal. In vivo HAL up-regulated MMP-3 and -13 mRNA expression 1.5- and 2-fold, respectively, in cirrhotic rats, whereas tissue inhibitor of metalloproteinase-1 was suppressed by 50%. In conclusion, submicromolar concentrations of HAL inhibit HSC proliferation and migration and up-regulate their expression of fibrolytic MMP-3 and -13 via activation of p38 MAPK and NF{kappa}B. The remarkable induction of MMP-3 and -13 makes HAL a promising agent for antifibrotic combination therapies.


Received for publication, January 3, 2006

* This work was supported in part by the Deutsche Forschungsgemeinschaft (DFG, Grant 646/14-1), by the German Competence Network for Viral Hepatitis, and by the Interdisciplinary Center for Clinical Research of the University of Erlangen-Nuernberg (to D. S.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Recipient of Yamanouchi (2002) and Sheila Sherlock (2003) Fellowships of the European Association for the Study of the Liver.

2 Recipient of a scholarship of the DFG graduate college (GRK 750).

3 To whom correspondence should be addressed: Division of Gastroenterology and Hepatology, Beth Israel Deaconess MC, Harvard Medical School, Dana 501, 330 Brookline Ave, Boston, MA 02215. Tel.: 617-667-8377; Fax: 617-667-2767; E-mail: dschuppa{at}bidmc.harvard.edu.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
P. Fu, J. A. Thompson, and L. A. Bach
Promotion of Cancer Cell Migration: AN INSULIN-LIKE GROWTH FACTOR (IGF)-INDEPENDENT ACTION OF IGF-BINDING PROTEIN-6
J. Biol. Chem., August 3, 2007; 282(31): 22298 - 22306.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. A. Fallowfield, M. Mizuno, T. J. Kendall, C. M. Constandinou, R. C. Benyon, J. S. Duffield, and J. P. Iredale
Scar-Associated Macrophages Are a Major Source of Hepatic Matrix Metalloproteinase-13 and Facilitate the Resolution of Murine Hepatic Fibrosis
J. Immunol., April 15, 2007; 178(8): 5288 - 5295.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2006 by the American Society for Biochemistry and Molecular Biology.